WAT · Waters Corporation
$304.242026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$471
+54.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($187 · $481) Analysts Range ($350 · $480) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $2.8B | — | 31.4% | 14.1% | $752MM | −$115MM | $637MM | 8.6% | — | 41.4% | $1.8B | $11.59 | — |
| 2022.Q4 | $3.0B | 6.7% | 31.3% | 15.5% | $786MM | −$378MM | $408MM | 9.3% | — | 39.9% | $2.1B | $11.84 | — |
| 2023.Q4 | $3.0B | -0.5% | 29.5% | 12.8% | $760MM | −$1.6B | −$806MM | 9.0% | — | 26.4% | $3.6B | $10.75 | — |
| 2024.Q4 | $3.0B | 0.1% | 29.7% | 15.5% | $744MM | −$115MM | $629MM | 9.6% | — | 20.4% | $3.7B | $10.67 | — |
| 2025.Q4 | $3.2B | 7.0% | 28.3% | 14.9% | $764MM | −$142MM | $622MM | 9.7% | — | 20.1% | $3.9B | $10.75 | 20.3 |
| italics below = DCF projection · 10yr Rev CAGR: 13.3% |
| 2026.Q4 | $6.2B | +96.2% | 30.1% | 15.4% | $1.6B | −$375MM | $1.2B | 9.4% | $1.1B | 38.4% | $4.3B | $24.84 | 12.2 |
| 2027.Q4 | $7.1B | +14.0% | 30.4% | 15.9% | $1.8B | −$117MM | $1.7B | 9.3% | $1.4B | 41.5% | $4.4B | $28.47 | 10.7 |
| 2028.Q4 | $7.5B | +6.1% | 31.9% | 16.4% | $2.0B | −$64MM | $1.9B | 9.2% | $1.5B | 44.9% | $4.5B | $31.42 | 9.7 |
| 2029.Q4 | $8.0B | +7.2% | 32.6% | 16.9% | $2.2B | −$91MM | $2.1B | 9.2% | $1.5B | 48.0% | $4.6B | $34.23 | 8.9 |
| 2030.Q4 | $8.6B | +6.7% | 32.6% | 17.4% | $2.3B | −$102MM | $2.2B | 9.1% | $1.4B | 49.9% | $4.7B | $36.29 | 8.4 |
|
| Term. Yr+ | $11.5B | 4.1% | 22.9% | 20.0% | $2.1B | −$365MM | $1.7B | 8.6% | $16.3B | 23.6% | — | — | — |
Active scenario IV: $471 (+54.7% vs market)